Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review

Kenneth R. Kaufman; Arnaldo E. Velez; Stephen Wong; Ram Mani

doi:10.1016/j.ebcr.2012.10.006

Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review

Kenneth R. Kaufman, Arnaldo E. Velez, Stephen Wong, Ram Mani

Rutgers, The State University

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

Original language	American English
Pages (from-to)	22-25
Number of pages	4
Journal	Epilepsy and Behavior Case Reports
Volume	1
Issue number	1
DOIs	https://doi.org/10.1016/j.ebcr.2012.10.006
State	Published - 2013

ASJC Scopus subject areas

Neurology
Clinical Neurology
Behavioral Neuroscience

Keywords

Atrial fibrillation
Cardiac adverse events
Complex partial status epilepticus
Education
Epilepsy
Lacosamide
Low dose
Video-EEG

Access to Document

10.1016/j.ebcr.2012.10.006

Cite this

@article{0c4c861f7b8647d593a74eb1f5be29bd,

title = "Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review",

abstract = "Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.",

keywords = "Atrial fibrillation, Cardiac adverse events, Complex partial status epilepticus, Education, Epilepsy, Lacosamide, Low dose, Video-EEG",

author = "Kaufman, \{Kenneth R.\} and Velez, \{Arnaldo E.\} and Stephen Wong and Ram Mani",

year = "2013",

doi = "10.1016/j.ebcr.2012.10.006",

language = "American English",

volume = "1",

pages = "22--25",

journal = "Epilepsy and Behavior Case Reports",

issn = "2213-3232",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Low-dose lacosamide-induced atrial fibrillation

T2 - Case analysis with literature review

AU - Kaufman, Kenneth R.

AU - Velez, Arnaldo E.

AU - Wong, Stephen

AU - Mani, Ram

PY - 2013

Y1 - 2013

N2 - Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

AB - Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

KW - Atrial fibrillation

KW - Cardiac adverse events

KW - Complex partial status epilepticus

KW - Education

KW - Epilepsy

KW - Lacosamide

KW - Low dose

KW - Video-EEG

UR - https://www.scopus.com/pages/publications/84876346492

UR - https://www.scopus.com/inward/citedby.url?scp=84876346492&partnerID=8YFLogxK

U2 - 10.1016/j.ebcr.2012.10.006

DO - 10.1016/j.ebcr.2012.10.006

M3 - Article

SN - 2213-3232

VL - 1

SP - 22

EP - 25

JO - Epilepsy and Behavior Case Reports

JF - Epilepsy and Behavior Case Reports

IS - 1

ER -

Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review

Abstract

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this